The agent of choice for terminal colon cancer pain is

Reading File
Finding Sources
Finding Sources
Reading File
Reading File

Agent of Choice for Terminal Colon Cancer Pain: Morphine

Morphine is the drug of choice for pain management in terminal colon cancer (and cancer pain in general). It is the gold-standard opioid analgesic for severe, intractable pain at end of life.

Why Morphine?

  • High intrinsic opioid activity - it acts on mu (μ) opioid receptors and is highly effective against the dull, constant, visceral pain typical of terminal cancer
  • Continuous/fixed-interval dosing - dosing on a fixed schedule (rather than "as needed") is more effective for cancer pain than PRN dosing
  • Multiple routes available - oral (including sustained-release formulations like MS Contin), IV, subcutaneous, and intrathecal administration
  • IV morphine peaks in 5-15 minutes, allowing rapid titration in a pain crisis
  • Parenteral breakthrough dosing - for a terminal patient in a pain crisis, the initial parenteral breakthrough dose should be 10% of the 24-hour total opioid dose, with doubling as needed

WHO Pain Ladder (Guiding Framework)

The World Health Organization Analgesic Ladder guides cancer pain management:
  1. Step 1 - Non-opioids (NSAIDs, acetaminophen) for mild pain
  2. Step 2 - Weak opioids (codeine, tramadol) for moderate pain
  3. Step 3 - Strong opioids (morphine, fentanyl, oxycodone) for severe/terminal pain
Terminal colon cancer pain falls at Step 3, where morphine is the prototype agent.

Practical Points

FeatureDetail
FormulationIV, oral immediate-release, oral sustained-release (MS Contin)
Dosing strategyFixed-interval (scheduled), not PRN
Breakthrough crisis10% of 24-hour dose IV; double dose until relief
AdjunctsNSAIDs (potentiate opioids), stimulant laxatives (prevent constipation)
AlternativeFentanyl patch if IV access limited (note: 12 hr onset, 24 hr to steady state)
Key point: Constipation from opioids does NOT develop tolerance - always co-prescribe a stimulant laxative with morphine.

Sources: Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 885; Rosen's Emergency Medicine, p. 3647
This is a shared conversation. Sign in to Orris to start your own chat.